AI Generated Image
An FDA Panel Just Endorsed These Unproven Peptides
WIRED • • business
Key Points:
- An FDA advisory committee narrowly voted to recommend reclassifying three peptides—BPC-157, KPV, and TB-500—to allow compounding pharmacies to legally dispense them, while MOTs-C received a less decisive vote.
- These peptides, popularized by influencers like Joe Rogan and promoted for various health benefits, currently exist mostly in an unregulated gray market with safety concerns and lack of robust scientific evidence.
- FDA scientists advised against approving these peptides due to insufficient safety and efficacy data, but some healthcare providers argued that regulated compounding could reduce risks compared to the gray market.
- Critics warn that FDA approval for compounding might confuse patients into thinking these peptides are fully approved drugs, and that a gray market will likely persist regardless of regulatory changes.
- The panel includes members with ties to peptide-related businesses, and additional peptides are under consideration, reflecting growing interest amid ongoing debates about safety and regulation.
